Aneurysmal Subarachnoid Hemorrhage Clinical Trial
Official title:
Prognostic Value of Circulating Endothelial Progenitor Cells in Aneurysmal Subarachnoid Hemorrhage (Evaluation de l'intérêt Pronostic Des progéniteurs endothéliaux Circulants Dans l'hémorragie Sous-arachnoïdienne Par Rupture d'anévrysme cérébral)
Aneurysmal subarachnoid hemorrhage is a common and serious disease associated to a high rate
of mortality and morbidity. Severe definitive neurological impairment can concern up to 30%
of patients in relation with elevated intracranial pressure, hemorrhage recurrence and
symptomatic cerebral arterial vasospasm. This latter complication is defined as a reversible
reduction of cerebral artery's diameter occurring between the 4th and the 14th day after
bleeding. Physiopathology is not well understood, but could involve endothelium, trough
endothelial progenitor cells (EPC). Circulating EPC are bone marrow-derived cells with
capacity of vasculogenesis and angiogenesis. EPC have been recognized playing a beneficial
role in cardiovascular disease and ischemic stroke. EPC have never been studied in
aneurysmal subarachnoid hemorrhage.
The primary objective of this study is to compare the number of circulating endothelial
progenitor cells between patients with a good neurological outcome (defined as a glasgow
outcome scale = 1 or 2) and patients with a poor neurological outcome (glasgow outcome scale
= 3, 4 or 5).
Briefly, the number of circulating EPC will be measured at admission, and at day 3, 6, 10,
14, 21 in each consecutive patient suffering aneurysmal subarachnoid hemorrhage and
hospitalized in Teaching Hospital of Besançon (France). The neurological outcome will be
measured one year after subarachnoid hemorrhage.
n/a
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03209830 -
Pharmaceutical Treatment of Fatigue After Aneurysmal Subarachnoid Hemorrhage
|
Phase 2 | |
Completed |
NCT05131295 -
Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage.
|
Phase 3 | |
Recruiting |
NCT04583163 -
Variability in Transcranial Doppler Technique in Neuro-Critical Care Patients
|
||
Not yet recruiting |
NCT03271697 -
Astragalus Membranaceus on Aneurysmal Subarachnoid Hemorrhage
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05483751 -
Micro- and Macrovascular Parameters in Delayed Cerebral Ischemia
|
||
Recruiting |
NCT01098890 -
Intraventricular Tissue Plasminogen Activator (tPA) in the Management of Aneurysmal Subarachnoid Hemorrhage
|
Phase 2 | |
Completed |
NCT00692744 -
Quality of Life in Elderly After Aneurysmal Subarachnoid Hemorrhage (SAH)
|
N/A | |
Recruiting |
NCT05738083 -
Machine Learning-based Prediction of Complications, Disability, and Death in Patients With aSAH
|
||
Completed |
NCT03754335 -
SubArachnoid Hemorrhage HEadache Treated by Lumbar Puncture
|
N/A | |
Completed |
NCT06076590 -
Impact of Multiple Electrolytes Injection Ⅱ and Saline on Hyperchloremia in Patients With Aneurysmal Subarachnoid Hemorrhage:a Pilot Study
|
Phase 4 | |
Recruiting |
NCT04148105 -
Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH)
|
Phase 4 | |
Recruiting |
NCT04548401 -
Effect of Antiplatelet Therapy on Cognition After Aneurysmal Subarachnoid Hemorrhage
|
||
Recruiting |
NCT02129413 -
Safety Study of Carotid Body Neurostimulation to Treat Cerebral Vasospasm
|
N/A | |
Terminated |
NCT00487461 -
Use of Simvastatin for the Prevention of Vasospasm in Aneurysmal Subarachnoid Hemorrhage
|
N/A | |
Recruiting |
NCT05974111 -
COAgulation Disorders in Ischaemic and Haemorrhagic Stroke
|
||
Not yet recruiting |
NCT06288659 -
aSAH Treatment Based on Intraventricular ICP Monitoring: A Prospective, Multicenter, Randomized and Controlled Trial
|
N/A | |
Recruiting |
NCT03706768 -
Degradation of the Glycocalyx in Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage
|
N/A | |
Recruiting |
NCT06284642 -
Early Lumbar Drainage Combined With Intrathecal Urokinase Injection for Treatment of Severe Aneurysmal SAH (LD-ITUK)
|
Phase 4 | |
Completed |
NCT02026596 -
SpareBrain - Mechanisms and Prevention of Secondary Brain Injury in Subarachnoid Haemorrhage
|
N/A | |
Recruiting |
NCT04566991 -
Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)
|
Phase 2 |